Galit Livnat

Merkaz Hakarmel, HA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Correlation between pulmonary outcomes and nutritional status following treatment with elexacaftor/tezacaftor/ivacaftor in people with Cystic fibrosis.

Correlation between pulmonary outcomes and nutritional status following treatment with elexacaftor/tezacaftor/ivacaftor in people with Cystic fibrosis.

Journal: Respiratory medicine

Published: February 23, 2026

Pulmonary exacerbations in cystic fibrosis after fatherhood with and without CFTR modulators.

Pulmonary exacerbations in cystic fibrosis after fatherhood with and without CFTR modulators.

Journal: Respiratory medicine

Published: December 10, 2025

Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross-Sectional Study in Israel.

Vaccine Coverage Among People With Cystic Fibrosis: A National Multicenter Cross-Sectional Study in Israel.

Journal: Pediatric pulmonology

Published: February 22, 2025

Nasal potential difference in young children is feasible - Report from a national referral center.

Nasal potential difference in young children is feasible - Report from a national referral center.

Journal: Respiratory medicine

Published: January 10, 2025

Medical clown intervention shortens length of hospitalization in children with pneumonia.

Medical clown intervention shortens length of hospitalization in children with pneumonia.

Journal: Scientific reports

Published: January 06, 2025

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational Study.

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis with Mildly Decreased and Normal Lung Function: A Real-Life Observational Study.

Journal: Annals of the American Thoracic Society

Published: July 25, 2024

Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Q359K/T360K variant.

Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Q359K/T360K variant.

Journal: ERJ open research

Published: April 14, 2024

Maternal and fetal outcomes in multiparous women with Cystic Fibrosis.

Maternal and fetal outcomes in multiparous women with Cystic Fibrosis.

Journal: Respiratory medicine

Published: October 29, 2023

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform.

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform.

Journal: Frontiers in pediatrics

Published: September 23, 2023

The new face of cystic fibrosis in the era of population genetic carrier screening.

The new face of cystic fibrosis in the era of population genetic carrier screening.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: August 03, 2023

Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.

Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Cohort Study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 10, 2023

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 06, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026